Recently, the Food and Drug Administration has granted approval for the PI3K inhibitor alpelisib for hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer (in combination with fulvestrant). This evidence concerns the gene ERBB2 and breast cancer.